Endometrial Cancer

After the 3-arm, JAVELIN Ovarian 100 trial terminated at the interim analysis, researchers concluded that avelumab is not yet a suitable first-line treatment option for patients with advanced epithelial cancer.

Adherence to current clinical guidelines may contribute to systematic underdiagnosis in Black women, says Kemi M. Doll, MD, MS.

The regulatory decision is based on findings from collective data from the dMMR endometrial cancer cohort A1 and the dMMR solid-tumor, non-endometrial cancer, cohort F of the ongoing phase 1 GARNET trial (NCT02715284).

The FDA approved dostarlimab (Jemperli) for the treatment of patients with recurrent or advanced endometrial cancer that progressed on or after platinum-containing chemotherapy and whose cancer is DNA mismatch repair deficient (dMMR), as determined by an FDA-approved test.

A reduction in patient-reported symptomatic adverse events (AEs) was observed with intensity-modulated radiotherapy (IMRT) compared with standard radiotherapy in patients with cervical or endometrial cancer, whereas no difference was observed with regard to clinician-reported AE.

Retrospective results showed that African-American women with endometrial cancer are less likely to receive evidence-based care compared with white women.

The FDA has granted accelerated approval to the combination of lenvatinib and pembrolizumab in the treatment of patients with advanced endometrial carcinoma.

The FDA approved entrectinib for pediatric and adult patients with certain subtypes of solid tumors, including non-small cell lung cancer.

The FDA has granted a second breakthrough therapy designation to the combination use of lenvatinib (Lenvima) and pembrolizumab (Keytruda) for the treatment of patients with advanced and/or metastatic non–microsatellite instability high (MSI-H)/proficient mismatch repair endometrial carcinoma who have progressed after ≥1 prior systemic therapy.

A study done at SUNY Downstate Hospital found that black women of Caribbean descent with type I or type II endometrial cancer expressed significant differences in genetic variations when compared with a nationwide population of patients with endometrial cancer.

Survivors of endometrial cancer are at higher risk for long-term cardiovascular problems such as phlebitis, thrombophlebitis, pulmonary heart disease, hypotension and atrial fibrillation.

A recent study suggested that intentional weight loss could decrease the risk of endometrial cancer.

A recent study shows that expedited surgery for patients with endometrial cancer is linked to an increased risk of mortality.

A recent study links NSAID use to an increased risk of endometrial carcinoma­–specific mortality.

"Real Housewives of Beverly Hills" star Camille Grammer discusses how she worked to diminish the shame behind gynecologic cancers.

Pelvic IMRT causes less GI, GU toxicities than standard pelvic radiation therapy for patients with gynecologic cancers.

Donna Clark, RN, Mitchell Cancer Institute, discusses what it was like to be a patient with endometrial cancer after more than two decades of being an oncology nurse.

Rates of endometrial cancer continue to increase among all racial and ethnic groups, but they're rising faster among non-Hispanic black women who also have poorer outcomes when compared with their white, non-Hispanic counterparts.

Oral contraceptives may provide long-term protection against endometrial cancer.

Camille Grammer, Real Housewife of Beverly Hills and one-year survivor of endometrial cancer, will lend her voice and celebrity to raising awareness about gynecologic cancers by serving as Chair of the 2015 National Race to End Women's Cancer to be held Sunday, Nov. 8 in Washington, D.C.

Endometrial cancer is the most common gynecologic cancer and the fourth most common cancer.